Compare TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock vs Twist Bioscience Corp — how do they compare? TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $235.36 (market cap $44.37B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 8.1× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals.
| TTWO | TWST | |
|---|---|---|
Market Cap | $44.37B | $5.45B |
Sector | Media | Health |
52-Week High | $262.29 | $102.88 |
52-Week Low | $189.69 | $24.16 |
Enterprise Value | $45.34B | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Take-Two Interactive (TTWO) trades at $235.93, down 0.31% on the day, with a neutral technical signal despite recent earnings beats. The company shows strong revenue growth to $5.63 billion in 2025 but faces profitability challenges with a net income margin of -4.48%. Analyst sentiment remains overwhelmingly positive with a 78.95% buy rating and a consensus price target of $302.50, driven by anticipation for Grand Theft Auto VI.
The outlook hinges on GTA VI execution, with potential for significant upside if launch succeeds, but risks include persistent negative cash flow from operations and high debt levels. Investors should weigh strong analyst confidence against fundamental weaknesses in profitability and cash generation.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
